ASX Growth Companies With High Insider Ownership September 2026

In the wake of the recent RBA rate increase, the Australian market is experiencing a period of volatility, with mixed signals from global markets and fluctuating commodity prices adding to investor uncertainty. Amidst these conditions, growth companies with high insider ownership can offer unique insights into potential resilience and alignment between management and shareholder interests, making them noteworthy in today's economic climate.

Top 10 Growth Companies With High Insider Ownership In Australia

Name	Insider Ownership	Earnings Growth
Wisr (ASX:WZR)	10.3%	94.2%
Starpharma Holdings (ASX:SPL)	19.3%	75.1%
SKS Technologies Group (ASX:SKS)	19.3%	27.7%
PDI Gold (ASX:PDI)	10.4%	55.2%
Forrestania Resources (ASX:FRS)	24.8%	72.9%
Emerald Resources (ASX:EMR)	18.3%	32.1%
Elsight (ASX:ELS)	12.5%	58.5%
Austral Resources Australia (ASX:AR1)	24%	28.2%
Adveritas (ASX:AV1)	17.6%	99.9%
Advanced Engineered Materials (ASX:AEM)	35.1%	58.7%

Click here to see the full list of 115 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Echo IQ (ASX:EIQ)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Echo IQ Limited is an AI and medical technology company focused on developing AI solutions for cardiac diagnostics in Australia, with a market cap of A$444.43 million.

Operations: The company's revenue segment consists of A$0.09 million from the development of artificial intelligence software for cardiac diagnostics.

Insider Ownership: 17.6%

Echo IQ, with high insider ownership, is poised for substantial growth despite recent volatility. The company forecasts a remarkable 97.2% annual revenue increase, outpacing the market significantly. Recent strategic moves include adding experienced healthcare investor Scott Wilkin to its board to bolster US market expansion efforts. Despite reporting a net loss of A$18.57 million for the year ending June 2026, Echo IQ completed an A$110 million equity offering to support its ambitious growth plans.

• Click to explore a detailed breakdown of our findings in Echo IQ's earnings growth report.
• The analysis detailed in our Echo IQ valuation report hints at an inflated share price compared to its estimated value.

Guzman y Gomez (ASX:GYG)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Guzman y Gomez Limited operates and manages quick service restaurants in Australia, Singapore, and Japan with a market cap of A$2.47 billion.

Operations: The company's revenue is primarily generated from its quick service restaurants, totaling A$551.75 million.

Insider Ownership: 17.1%

Guzman y Gomez demonstrates potential for growth with high insider ownership and a forecasted earnings growth of 20.4% annually, outpacing the Australian market. Despite reporting a net loss of A$26.7 million for fiscal year 2026, the company plans to expand by opening 35 new restaurants in Australia next year. Recent announcements include fully franked dividends, indicating strong cash flow management amid ambitious expansion plans and expected significant earnings improvement over the next three years.

• Unlock comprehensive insights into our analysis of Guzman y Gomez stock in this growth report.
• Insights from our recent valuation report point to the potential overvaluation of Guzman y Gomez shares in the market.

Mesoblast (ASX:MSB)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Mesoblast Limited, along with its subsidiaries, focuses on developing regenerative medicine products in Australia and has a market cap of A$2.74 billion.

Operations: The company generates revenue of $120.25 million from the development and commercialization of its allogeneic cellular medicines platform.

Insider Ownership: 33.1%

Mesoblast's insider ownership aligns with its growth trajectory, as the company forecasts significant revenue growth of 37.3% annually, surpassing market averages. Recent FDA approval for a new potency assay enhances product quality control for Ryoncil, their MSC therapy. Despite a net loss of US$57.5 million in fiscal year 2026, Mesoblast shows promise with expected profitability within three years and ongoing Phase 3 trials for rexlemestrocel-L targeting chronic low back pain.

• Get an in-depth perspective on Mesoblast's performance by reading our analyst estimates report here.
• Upon reviewing our latest valuation report, Mesoblast's share price might be too optimistic.

Make It Happen

• Reveal the 115 hidden gems among our Fast Growing ASX Companies With High Insider Ownership screener with a single click here.
• Interested In Other Possibilities? Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com